CN1630666A - 因子ⅷc2结构域变体 - Google Patents

因子ⅷc2结构域变体 Download PDF

Info

Publication number
CN1630666A
CN1630666A CNA028238451A CN02823845A CN1630666A CN 1630666 A CN1630666 A CN 1630666A CN A028238451 A CNA028238451 A CN A028238451A CN 02823845 A CN02823845 A CN 02823845A CN 1630666 A CN1630666 A CN 1630666A
Authority
CN
China
Prior art keywords
ser
leu
factor viii
glu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028238451A
Other languages
English (en)
Chinese (zh)
Inventor
J·S·劳拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AMORY UNIV
Original Assignee
AMORY UNIV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AMORY UNIV filed Critical AMORY UNIV
Publication of CN1630666A publication Critical patent/CN1630666A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNA028238451A 2001-11-30 2002-11-27 因子ⅷc2结构域变体 Pending CN1630666A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33456901P 2001-11-30 2001-11-30
US60/334,569 2001-11-30

Publications (1)

Publication Number Publication Date
CN1630666A true CN1630666A (zh) 2005-06-22

Family

ID=23307813

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028238451A Pending CN1630666A (zh) 2001-11-30 2002-11-27 因子ⅷc2结构域变体

Country Status (8)

Country Link
US (1) US20040249134A1 (enExample)
EP (1) EP1456235A4 (enExample)
JP (1) JP2005511038A (enExample)
CN (1) CN1630666A (enExample)
AU (1) AU2002364509A1 (enExample)
CA (1) CA2462966A1 (enExample)
MX (1) MXPA04005079A (enExample)
WO (1) WO2003047507A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US7709224B2 (en) 2003-06-03 2010-05-04 Biosante Pharmaceuticals, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050123997A1 (en) * 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
EP1750733B1 (en) * 2004-05-03 2013-12-11 Emory University METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII
MY185597A (en) * 2005-09-20 2021-05-24 Avantor Performance Mat Inc Vegetarian protein a preparation and methods thereof
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
IT1394522B1 (it) 2009-01-09 2012-07-05 Invatec Technology Ct Gmbh Dispositivo medicale con rilascio di farmaco
EP2498804A4 (en) * 2009-11-13 2013-05-08 Puget Sound Blood Ct FACTOR VIII B CELL EPITOPARIANTS WITH REDUCED IMMUNOGENITY
MX2012005527A (es) 2009-11-13 2012-08-08 Grifols Therapeutics Inc Preparaciones que contienen el factor de von willebrand (fvw) procedimientos, kits y aplicaciones relacionados con las mismas.
EP3466968A1 (en) * 2010-09-15 2019-04-10 Stichting Sanquin Bloedvoorziening Factor viii variants having a decreased cellular uptake
US9150637B2 (en) 2010-11-05 2015-10-06 Baxalta Inc. Variant of antihemophilic factor VIII having increased specific activity
WO2015127129A1 (en) * 2014-02-19 2015-08-27 Bloodworks Factor viii b cell epitope variants having reduced immunogenicity
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
WO2025164792A1 (ja) * 2024-02-02 2025-08-07 学校法人自治医科大学 高比活性／高分泌発現型の第ｖｉｉｉ因子改変体、高発現型の第ｖｉｉｉ因子コード核酸及びそれらの用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
JPH0788399B2 (ja) * 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
US5004803A (en) * 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US6376463B1 (en) * 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
WO2002024723A1 (en) * 2000-09-19 2002-03-28 Emory University Modified factor viii

Also Published As

Publication number Publication date
EP1456235A2 (en) 2004-09-15
WO2003047507A3 (en) 2003-07-17
WO2003047507A2 (en) 2003-06-12
MXPA04005079A (es) 2004-08-19
CA2462966A1 (en) 2003-06-12
EP1456235A4 (en) 2005-08-17
US20040249134A1 (en) 2004-12-09
JP2005511038A (ja) 2005-04-28
AU2002364509A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
CN1224627C (zh) 修饰的凝血因子ⅷ
CN1205221C (zh) 修饰的凝血因子ⅷ
CN1191360C (zh) 修饰的凝血因子ⅷ
CN1033760C (zh) 产生具有第八因子活性的第八因子缺失突变体的方法
AU2007269233B2 (en) Method of producing Factor VIII proteins by recombinant methods
CN1630666A (zh) 因子ⅷc2结构域变体
EP0910628B1 (en) Inactivation resistant factor viii
AU693837B2 (en) Hybrid human/animal factor VIII
CN1745100A (zh) 因子ⅷ多肽
KR20150036510A (ko) Xten 및 폰 빌레브란트 인자 단백질과의 viii 인자 복합체 및 이의 용도
WO1997040145A9 (en) Inactivation resistant factor viii
CN1262688A (zh) 整合蛋白结合肽及其应用
US20130072434A1 (en) Inactivation resistant factor viii
WO2012170289A1 (en) Method of producing factor viii proteins by recombinant methods
WO2003087355A1 (en) Inactivation resistant factor viii
US20140357565A1 (en) Method of producing factor viii proteins by recombinant methods
CN1518558A (zh) 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途
US20040005670A1 (en) Compositions and methods for the treatment of hemophilia A
CN1553955A (zh) 血小板糖蛋白IBα融合多肽和其利用的方法
CN1823090A (zh) 血小板糖蛋白IB－α变体融合多肽及其用法
CN1179976C (zh) 产生凝血因子ⅷ的生产方法和宿主细胞
US20090203077A1 (en) Method of producing factor viii proteins by recombinant methods
CN1709912A (zh) 一种抑制囊膜病毒感染的多螺旋蛋白及其编码基因与应用
HK1178545A (en) Method of producing factor viii proteins by recombinant methods
CN1040203A (zh) 抗聚集肽

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned